Connect with us

Health

Proteins Found In Quorn Beat Regular Whey Shakes, Should You Switch?

It may have outweighed typical whey protein shakes, but its “always-on-the-go customers” might think twice.

Published

on

Source: Depositphotos

People who visit the gym frequently, and are working hard to build those muscles, understand how protein becomes a quintessential part of their diet. Today’s latest discovery found that protein found in Quorn does better than the typical whey protein shakes we’re accustomed to. The question is, should you switch?

A team of researchers from the University of Exeter conducted the study — the same team who are understanding Quorn’s composition and how these plant-based proteins are a better choice for muscle development compared to animal-derived protein sources.

Proteins are a great source of amino acids and an efficient muscle builder, especially for those coming after a workout. Mainly, proteins help the muscles repair itself from a cellular level and encourages these muscles to grow during its repair process.

In the typical human diet, protein is a source of around 10% to 15% of the body’s energy and is the second most common compound in the body, behind water.

According to the British Nutrition Foundation, adults should at least consume 0.75g of protein each day per kg of body weight. This is equal to 56g per day for someone who weighs 75kg (118lbs) — about the amount found in two chicken breasts.

But for active people, they need to consume more protein for repairing muscles and recovering after exercise.

Popularly, most fitness enthusiasts opt to choose whey protein shakes as a post-workout snack to supply the much-needed protein in their bodies efficiently and conveniently.

Meanwhile, mycoprotein takes it even further.

Mycoprotein comes from a type of fungi found in soil called Fusarium Venenatum. The data presented at the European College of Sport Science (ECSS) conference demonstrated that it is a more effective source of protein to support post-exercise muscle building compared to animal-sourced protein.

“These results are very encouraging when we consider the desire of some individuals to choose non-animal derived sources of protein to support muscle mass maintenance or adaptations with training,” said Dr. Benjamin Wall, Associate Professor of Nutritional Physiology, University of Exeter.

“Our data show that mycoprotein can stimulate muscles to grow faster in the hours following exercise compared with a typical animal comparator protein (milk protein) – we look forward to seeing whether these mechanistic findings translate to longer-term training studies in various populations.”

Particularly, Quorn claims that mycoprotein is the core ingredient in all its products. And according to their research, mycoprotein performed twice as much than regular whey proteins compared to the typically animal-sourced milk protein.

In their experiment, the researchers had 20 healthy and trained young men consume protein shakes after performing a regular leg workout. In one set, they were made to have mycoprotein-based shakes, while the other took the typical animal-based shake.

Their muscle building rates were then measured using stable isotope labeled “tracers” in the hours following protein consumption.

Based on the results, milk protein increased muscle building rates by 60%. Meanwhile, mycoprotein increased muscle building rates by more than double (the article did not provide the exact number of growth gained).

If anything holds, it’s that mycoprotein poses as a great alternative to meat and animal-based food. Also, it has great potential to supplement the rising lack of protein consumption globally and decrease the reliance on meat.

The British Nutrition Foundation already recommends mycoprotein as a good source of dietary protein, both for everyday life and for sport and exercise.

Tim Finnigan, Chief Scientific Adviser for Quorn Foods, said “we’re excited to see this data being presented by the University of Exeter at ECSS. In a world where many people are trying to cut back on their meat consumption, either for environmental or health reasons, we’re happy to be able to offer an alternative protein that can provide exceptional nutrition and muscle growth, all while being meat-free.”

In conversations whether mycoprotein — which The Exeter University considers as unique to Quorn products — can replace the typical milk-based whey protein shakes; it may, however, be challenging to serve to most fast-paced customers.

Primarily, typical whey protein shakes is a simple solution that works effectively. The steps to prepare is a no brainer — you’ll just have to mix the powdered milk with water in a canister and drink it throughout the day.

Meanwhile, with Quorn, you’ll have to go through the nitty-gritty — especially in preparing your full meal made of Quorn products. In a sense, you need to allocate a significant amount of time to do so.

And for people rushing after a gym workout, and are not typically looking for a full meal made of Quorn product to supply their protein needs, the idea becomes less of a practical method. So unless Quorn makes a protein shake that caters to its on-the-go customers, the typical milk-based protein is going to stay.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

Germany Will Make Measles Vaccine Mandatory Through New Law

Germany aims to pass a new law to increase immunity coverage to 95% all throughout the country

Published

on

Photo by Artem Beliaikin on Unsplash

Germany is well on its way with establishing a new law that will compulsorily make parents give their children the needed measles vaccine — aiming to combat the resurging of the disease in the country.

Chancellor Angela Merkel’s cabinet decided Wednesday, July 17, that they will pass the Measles Protection Act, which was adopted July 19.

“Whether in kindergarten, at the childminder or at school, we want to protect all children against measles infection,” Jens Spahn, Germany’s Health Minister, said in a statement.

“Measles is extremely contagious and can take a very nasty, at times deadly, turn,” the Minister added.

The new law will require all German children to take the recommended vaccine shots before admission to kindergarten or school next year or before March 1, 2020.

The law is also mandatory over adults or staff working in daycare centers or other educational institutions.

Source: DPA

Furthermore, parents will have to prove that their children have been vaccinated before entering school or kindergarten through a vaccination certificate called “Kinderuntersuchungsheft,” which is a special booklet that parents fill out, documenting their child’s vaccines or by a medical certificate that shows that the child already had measles.

Reluctance or violating the law will receive a fine of up to 2,500 euros ($2,800) under the bill that is expected to pass quickly through the Bundestag lower house of parliament.

“We want to protect as many children as possible from measles infection,” said Health Minister Spahn, who is aiming for at least 95 percent coverage.

While 97 percent of German children had their first dose, the percentage that received the second dose dropped to 93 percent. Furthermore, some regions fall short on the desired quota at the federal level. The vaccination rate against measles in Germany is currently at 92.9 percent, but it has been falling in recent years.

Through this new law, German authorities hope to bump their coverage well above 95 percent, the level recommended by the World Health Organization to achieve a sturdy “herd immunity” against measles.

Furthermore, the new law also applies to doctors and other adults working in a community or medical facilities. In accordance, they too will also need to prove that they have had the required vaccinations. On top of that, the bill will also require asylum seekers and refugees to prove their vaccination status if they move into community accommodation.

The UN World Health Organization (WHO) has warned that global efforts to increase immunization coverage against deadly diseases are stagnating and is significantly contributing to the resurgence of measles worldwide.

Last year, 350,000 cases of measles were reported, more than double the number for 2017. In the same year, the most recent year for which estimates are available, measles killed close to 110,000 people.

In the first quarter of 2019, the number of reported measles cases globally increased fourfold as compared to the same period last year. The WHO has deemed vaccine hesitancy — the reluctance or refusal to vaccinate despite the availability of vaccines — a top 10 threat to global health this year.

The resurgence of the disease also relates to the hesitation and fear in developed countries, with the United States taking the lead on the highest rate of reported cases.

Particularly for Europe, who saw a large influx in measles cases, witnessed 82,596 new cases of measles in 2018 — a staggering 15 times the record low in 2016.

Germany was among the worst affected countries, with around 651 new measles cases being reported to the European Centre for Disease Prevention and Control (ECDC), and in the first months of this year, there are already more than 400 cases that have been reported. 

The report comes after Germany’s efforts of making vaccinations compulsory at a regional level in the state of Brandenburg. Today the country is making a full swing against the disease by enforcing the law throughout the country.

The law will still need the approval of the German parliament. But the large government majority is seemingly supportive of the move and is expected to pass without difficulty. However, the law is criticized by the Greens, who felt the vaccines should be encouraged, but not mandatory.

Related: New York Moves To Rule Out Religious Exemption For Vaccines

The resurgence of the disease in some countries has been blamed on the so-called “anti-vax” movement, which is largely based on a 1998 publication linking the measles vaccine and autism that has since been debunked.

Also faced with an increasing number of measle outbreaks, a handful of other countries around the world have introduced mandatory vaccinations, including France, Italy, and Australia. 

Continue Reading

Health

The Future Of Child Care: Smart Diapers

Lumi by Pampers is a smart diaper system that allows parents to track their babies’ sleeping and peeing patterns right off their smartphones.

Published

on

Photo: Lumi by Pampers Website

Recent technological advancements have made it possible to make everything we use in our daily lives smart — phones, locks, homes, remote controls, TV, and diapers. Yes, you read that right: smart diapers.

Pampers, the world’s leading diaper and infant product brand, is set to launch its take for smart diapers. The company announced that it would be launching the new smart diaper line, called Lumi, with the capability of tracking baby urination patterns and sending insights right into a parent’s smartphone.

“Beyond keeping them dry through the night, we wondered: how can we do more to support babies’ daily development?” the company asked as they start to develop the ingenious product.

“So we partnered with Verily and Logitech to create Lumi by Pampers — the world’s first all-in-one connected care system that’s revolutionizing baby monitoring by helping parents monitor and track their baby 24/7. By combining a video monitor with an activity sensor, Lumi helps parents blend real-time data with their intuition seamlessly and offers insights tailored to their unique baby using the Lumi by Pampers app.”

Pampers partnered with Verily, Alphabet Inc.’s research organization devoted to the study of life sciences, and Logitech, a Swiss provider of personal computers and mobile peripherals, to develop the said smart diaper, as well as, the Lumi app.

Furthermore, the smart diaper was also developed with the help of leading pediatricians, Dr. Wendy Sue Swanson, and Dr. Earl Young.

According to Pampers, Lumi has activity sensors that automatically tracks baby’s activities like wet diapers and sleep. And the information gathered by the diaper will be sent to an app which shows “routine, insights and all you need to know in one place.”

The initial package includes a ten-day pack of diapers, as well as, a 24-hour camera monitor. The 1080p wide-angle HD monitor with night vision and two-way audio also track room temperature and humidity. Additional packs of Lumi by Pamper diapers will be sold separately, and pricing has not been finalized yet.

Lumi can track “your baby’s sleep, so you know how much they’re getting.” According to Pampers, “sleep fuels the fastest rate of brain development, which happens between ages of 0-3.” The app also tracks your baby’s feeding, diapering, sleep routines, and critical milestones.

“With our all-in-one system, you can monitor your baby’s unique patterns and see emerging routines.”

Aside from that, Lumi also personalizes insights and sends a notification to the parents via the app. “Lumi offers content tailored to your baby from The Wonder Weeks® and our team of baby development experts, to help you better understand your baby’s overall development,” they said.

The concept of the smart diaper is part of a global movement called the Internet of Things (IoT), which allows users to track everything through the things that they commonly use — from the number of knocks on the door to the frequency of opening the refrigerator, and to how well someone brushes their teeth.

As IoT becomes an everyday innovation across all industry, baby’s healthcare has recently been flooded by new smart products to help new and old parents to track the progress of their babies’ growth. A similar concept was previously launched by Pampers’ competitor, Huggies, where their smart diapers have the capability of notifying parents every time their babies pooped.

Other products that have the IoT technology includes a robotic crib that was said to mimic the womb to help new infants sleep soundly and some onesies that double as a sleeping pattern tracker for babies.

Pediatricians around the world have been reminding parents to track their baby’s growth consistently. Tracking allows them to be alerted when the baby is constipated, or if the baby is dehydrated, among other things that might seem wrong based on aggregate data. This is particularly essential because early diagnosis helps parents secure their baby’s health more efficiently.

While there is a plethora of tracking apps already around the market, Lumi is the first that has an activity sensor that sends aggregate data directly to the parents and makes a smart analysis of “what is happening.” The problem with Lumi, however, is that it tops out at size four, and offers no further support after the baby outgrows them.

The product is yet to be available for public purchase, and the price has not been finalized yet. But Pampers opens a site where interest parents can pre-order Lumi on a waiting-list basis.

“60 years ago, we reimagined baby care with the first disposable diaper. Lumi by Pampers is the next step in our mission to continue re-inventing baby care,” reads Lumi’s website.

Continue Reading

Health

Israeli Researchers Test Drug That Starves Pancreatic Cancer Cells To Death

Isreali researchers believe that CPI-613 can effectively help expedite the process of curing pancreatic cancer of patients.

Published

on

Image by David Mark from Pixabay

Reimagining a conventional way of attacking cancer is Rafael Pharmaceuticals’ idea of aiding a more immediate way of treating patients with pancreatic cancer, which is one of the most leading causes of death from cancer in the world.

Israeli researchers from Rafael Pharmaceuticals launched a phase III clinical trial on Thursday for pancreatic cancer at eight sites throughout Israel, which the company sees as a breakthrough for the drug that they are developing.

Rafael Pharmaceuticals is a leader in the growing field of cancer metabolism-based therapeutics. Supplementarily, their approach to helping expedite the process of extinguishing pancreatic cancer from patients is to starve the cancer cells to death with the help of other existing medical solutions.

Meanwhile, the concept of starving cancer cells has been a long tried approach to attack the problem from the root—starve them enough to prevent them from dividing and cause eventual cell death. However, previous attempts have continuously failed to show much promise that proves it to become an effective track to follow.

As an effort, Rafael Pharmaceuticals is looking at a drug called CPI-613, which activates two key tricarboxylic acids (TCA) cycle enzymes called Pyruvate dehydrogenase and alpha-Ketoglutaric dehydrogenase. Particularly, these TCA cycle enzymes are responsible for signaling cells to release stored energy.

Basically, CPI-613 mimics the processes of chemical reactions performed by the two mentioned above TCA cycle enzymes. But specific to the drug, it “feeds misinformation to these regulatory elements, making them feel that there is too much carbon flow” and signal cancer cells to release stored energy. Essentially, the cells eventually die or weakened as a result.

Tim Pardee, Rafael’s Chief Medical Officer, also noted that the drug also offers many benefits: “[CPI-613] simultaneously inhibits both complexes so tumor cells that are primarily driven by glucose cannot utilize glucose in the TCA cycle. Tumor cells that are primarily driven by glutamine usage cannot use glutamine-derived carbons in the TCA cycle. And, importantly, tumors cannot switch from one source to the other in the presence of CPI-613.”

In other words, one benefit with their drug is that cancer cells cannot utilize their primary source of energy, such as glucose, to grow and replicate because CPI-613 feeds them information that there is already an abundance of which. While the second benefit is that for the cells to develop resistance to the drug is unlikely, and the third, the drug is highly selective; thus, it will hardly cause significant damage to healthy cells.

Pardee adds that CPI-613 combined with other existing treatments such as chemotherapy can effectively expedite the process of curing pancreatic cancer, at least that is what their clinical trial is trying to prove.

As of the moment, the researchers are looking to perform phase III on a group that they are calling the AVENGER 500, where the first 250 people diagnosed with late-stage pancreatic cancer will be administered CPI-613 with a chemotherapy combination of fluorouracil, leucovorin, irinotecan, and oxaliplatin, called FOLFIRINOX. Meanwhile, the next 250 will only receive chemotherapy treatment.

If the theory serves right, the pharmaceutical company will yield positive results by September 2020, and the company will be able to apply and receive expedited approval by the FDA. If not, he said that the earliest the drug would be on the market from this trial would be October 2021.

The trial kicked off at eight hospitals throughout the country, including Hillel Yaffe Medical Center, Yitzhak Shamir Medical Center, Soroka Medical Center, Sheba Medical Center, Rambam Health Care Campus, Laniado Hospital, Tel Aviv Sourasky Medical Center and Shaare Zedek Medical Center.

In particular with pancreatic cancer, it is the 12th most common cancer worldwide, with 458,918 new cases in 2018 alone. It is the fourth leading cause of cancer death and accounts for 7% of all cancer deaths, according to Cancer.Net.

Furthermore, the problematic thing about pancreatic cancer is that it is hard to detect early on, so researchers are hell-bent into finding solutions for the disease when it is already in its late stages, or it is already too late to administer early-on medical treatments.

Thus, the five-year survival rate for people with pancreatic cancer is 9%. For the 52% of people who are diagnosed after cancer has spread, the 5-year survival rate is 3%, Cancer.Net says.

“Every day, more than 1,200 people around the world receive a pancreatic cancer diagnosis, and our trial brings hope as the only Phase 3 clinical trial in metastatic pancreatic cancer,” said Sanjeev Luther, President and Chief Executive Officer of Rafael Pharmaceuticals. “The expansion of our trial into Israel is the first step in bringing our commitment to developing treatments for patients with significant unmet medical needs to a global level.”

Continue Reading

Trending